How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

416 results for

Migraine Medications in Breast Feeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Migraine Medications in Breast Feeding

Migraine Medications in Breast Feeding Migraine Medications in Breast Feeding Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Migraine (...) Medications in Breast Feeding Migraine Medications in Breast Feeding Aka: Migraine Medications in Breast Feeding , Headache Medications in Lactation II. Indications Postpartum s while lactating III. Management: Abortive medications considered Lactation compatible ( ) or (or ) Metoclopramide (Reglan) ( ) IV. Management: Prophylactic medications considered Lactation compatible V. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term

2018 FP Notebook

2. Migraine Medications in Breast Feeding

Migraine Medications in Breast Feeding Migraine Medications in Breast Feeding Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Migraine (...) Medications in Breast Feeding Migraine Medications in Breast Feeding Aka: Migraine Medications in Breast Feeding , Headache Medications in Lactation II. Indications Postpartum s while lactating III. Management: Abortive medications considered Lactation compatible ( ) or (or ) Metoclopramide (Reglan) ( ) IV. Management: Prophylactic medications considered Lactation compatible V. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term

2015 FP Notebook

3. Treating pain during pregnancy and breast feeding

Treating pain during pregnancy and breast feeding Treating pain during pregnancy and breast feeding | Evidence-Based Nursing blog by This week’s EBN Twitter Chat on Weds 19 th April at 8-9pm UK time will focus on pain during pregnancy, how important and difficult is to treat pain during pregnancy and breast feeding. The Twitter Chat will be hosted by Dr Massimo Allegri, Assistant Professor in Anesthesia Intensive Care and Pain Medicine at the University of Parma (Italy),@allegri_massimo (...) quality of life, but also outcome of patients who refer it. Unfortunately, pain continues to being undertreated and under-recognized. Chronic pain is not just a symptom but it is a real disease that needs an accurate diagnosis and appropriate therapy against the pain generator pathophysiology. This problem is even more important during pregnancy and breastfeeding. The fear to give drugs that can hurt foetus/neon ate can drive the physician to a “wait and see” approach that cannot solve the problem

2017 Evidence-Based Nursing blog

4. A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

). Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day) If female, pregnancy (defined as positive β-HCG blood test if applicable), breast-feeding. Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any (...) a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing. Drug: Sotagliflozin (SAR439954) Pharmaceutical form: tablets Route of administration: oral Drug: Ramipril Pharmaceutical form: tablets Route of administration: oral Outcome Measures Go to Primary Outcome Measures : Assessment of PK parameter: AUCtau [ Time Frame: On Day 10 (Period 2) ] Sotagliflozin

2018 Clinical Trials

5. Erenumab (Aimovig) - Migraine

Quality of Life Questionnaire MSQ-EF Migraine-specific Quality of Life Questionnaire – Emotional Function MSQ-RFP Migraine-specific Quality of Life Questionnaire – Role Function Preventive MSQ-RFR Migraine-specific Quality of Life Questionnaire – Role Function Restrictive N/A not applicable NF National formulary NGHC non-glycosylated heavy chain NSAID Non-steroidal anti-inflammatory drug PFS prefilled syringe Ph Eur European Pharmacopoeia PK Pharmacokinetic PMDA Pharmaceuticals and Medical Devices (...) of experiments DP drug product DS drug substance DSC differential scanning calorimetry eCRF electronic case report form eDiary electronic diary ELISA enzyme-linked immunosorbent assay EMA European Medicines Agency EM episodic migraine ESI-TOF-MS electrospray ionization time-of-flight mass spectrometry Fc fragment crystallizable FcRn neonatal Fc receptor FDA Food and Drug Administration (US) FVIP filtered viral inactivation pool HC Heavy chain HCCF Harvested cell culture fluid HCP host cell protein HIC

2018 European Medicines Agency - EPARs

6. Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value

Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value Evidence Report October 4, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Chronic Low Back and Neck Pain – Evidence Report AUTHORS: Jeffrey A. Tice, MD Professor of Medicine University of California, San Francisco Varun Kumar, MBBS (...) Report List of Acronyms Used in this Report AAPM American Academy of Pain Medicine AHRQ Agency for Healthcare Research and Quality ACP American College of Physicians AMSTAR A Measurement Tool to Assess Systematic Reviews APS American Pain Society CBT Cognitive Behavioral Therapy CDC Centers for Disease Control and Prevention CMS Centers for Medicare and Medicaid Services CPGS Chronic Pain Grade Scale FFbHR Functional questionnaire Hannover for everyday diagnosis of functional impairment by back pain

2017 California Technology Assessment Forum

7. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. From 1 Professor and Chair, Department of Nutrition Sciences, University of Alabama at Birmingham, Director, UAB Diabetes Research Center, GRECC Investigator & Staff Physician, Birmingham VA Medical Center, Birmingham, Alabama; 2 Director, Metabolic Support, Clinical Professor of Medicine, Division (...) School of Medicine, Internal Medicine, Endocrinology, Pediatrics, Pediatric Endocrinology, New Haven, Connecticut; 7 Walter Reed National Military Medical Center, Diabetes Obesity & Metabolic Institute, Bethesda, Maryland; 8 Assistant Clinical Professor, Mount Sinai School of Medicine, NY, ProHealth Care Associates, Division of Endocrinology, Lake Success, New York; 9 Center for Weight Management, Division of Endocrinology, Diabetes and Metabolism, Scripps Clinic, San Diego, California. Address

2016 American Association of Clinical Endocrinologists

8. Medical eligibility criteria for contraceptive use

for meta-analyses was provided by Rochelle Fu. Technical and copy-editing were provided by Jura Editorial Services (jura-eds.com) and Green Ink, United Kingdom (greenink.co.uk). Funding The development of this guideline was financially supported by the National Institutes of Health (NIH) and United States Agency for International Development (USAID).Medical eligibility criteria for contraceptive use - Executive summary | 3 Abbreviations ART antiretroviral therapy ARV antiretroviral (medication) ß-hCG (...) device CVR combined contraceptive vaginal ring CYP3A4 cytochrome P450 3A4 enzyme DMPA depot medroxyprogesterone acetate DMPA-IM depot medroxyprogesterone acetate – intramuscular DMPA-SC depot medroxyprogesterone acetate – subcutaneous DVT deep vein thrombosis ECP emergency contraceptive pill EE ethinyl estradiol E-IUD emergency intrauterine device EMA European Medicines Agency ETG etonogestrel FAB fertility awareness-based methods FDA United States Food and Drug Administration GDG Guideline

2015 World Health Organisation Guidelines

9. Ticagrelor Therapy for RefrACTORy Migraine Study

-depressants, anti-seizure medications, blood pressure medicines and others. The investigators have shown that in a small number of patients, a certain type of blood thinner (Clopidogrel) can reduce or eliminate migraine headaches in patients who also have a hole in the heart wall that allows flow from the right side of the heart to the left. Ticagrelor is a blood thinning drug which works in the same way as the clopidogrel, but is broken down by the body differently and thus allows everyone to use (...) therapy was effective (> 50% reduction in monthly headache days), the subject could elect to continue therapy for an additional two months (56 days), while continuing to complete daily headache logs. Condition or disease Intervention/treatment Phase Migraine Headache Migraine Headache Drug: Ticagrelor 90 mg twice per day Phase 4 Detailed Description: Migraine headaches are poorly understood, and can be severely debilitating. Many types of drugs have been tried in migraine sufferers including anti

2015 Clinical Trials

10. Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.

criteria. Medication-overuse headache and/or other primary headache disorders, according to IHS 2013 criteria. Change in migraine treatment in the twelve weeks prior to, or during the study. Taking ≥ 2 migraine prevention drugs. Failure to respond in ≥ 2 previous migraine prevention trials. Taking NAc, VitE or VitC supplements in the 12 weeks prior to the study. Pregnancy, or risk of pregnancy during the study; female of reproductive age not taking medically prescribed contraception; breast feeding (...) therapy has never been studied and if effective, will play an important role in migraine prevention. Condition or disease Intervention/treatment Phase Migraine, Headaches Drug: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 90 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator

2015 Clinical Trials

11. Migraine

3 months of treatment. After 6–12 months of successful therapy: Review the need for continuing migraine prophylaxis. Consider gradual drug withdrawal. Basis for recommendation Basis for recommendation The recommendations on preventative treatment for migraine are based on the clinical guidelines Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache [ ], Headaches in over 12s: diagnosis and management (...) and may be particularly useful where; drug treatment is contraindicated or poorly tolerated; there is a history of medication overuse headache; pregnancy is planned or during pregnancy or lactation; the person prefers to avoid drugs [ ; ; ]. Behavioural therapies — evidence suggests that therapies such as relaxation techniques, biofeedback, and cognitive behavioural therapy can be helpful for many people with migraine [ ; ; ]. SIGN recommends encouraging relaxation techniques such as mindfulness, yoga

2019 NICE Clinical Knowledge Summaries

12. A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

by a physician. History or presence of drug or alcohol abuse. If female, pregnancy or breast-feeding. Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any oral contraceptives during the screening period or for at least 15 days prior to the first dose of Period 1; any (...) be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days Drug: sotagliflozin (SAR439954) Pharmaceutical form: tablet Route of administration: oral Drug: midazolam Pharmaceutical form: HCl syrup Route of administration: oral Drug: metoprolol Pharmaceutical form: tablet Route of administration: oral Experimental: Cohort 2 Participants will initially be given with treatment A (cocktail of metoprolol

2016 Clinical Trials

13. Herbal Medication (Gongjin-dan) for Chronic Dizziness

of dizziness Aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), or creatinine > 3 × upper limit of normal range at baseline Women of (suspected) pregnancy or breast-feeding Allergic reactions to the study medications Suspicion of alcohol and/or drug abuse Enrollment in another clinical study presently or within 30 days prior to the initial administration of the study medications Difficulty in reliably communicating with the investigators or likelihood of inability (...) Estimated Primary Completion Date : August 30, 2020 Estimated Study Completion Date : August 30, 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Gongjin-dan Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days). Drug: Gongjin-Dan Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus

2017 Clinical Trials

14. A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

of sensitivity/idiosyncrasy to medicinal products or excipients. Positive HIV test. Positive hepatitis B or C test. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent (...) a pregnancy throughout the entire conduct of the study. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen (max 2 gram/day). Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disorders, renal and hepatic disorders (clinically relevant increased ALAT/ASAT or hyperbilirubinemia) hormonal disorders (especially diabetes mellitus

2015 Clinical Trials

15. A Drug-drug Interaction Study Between Daclatasvir and Metformin

). Documented history of sensitivity/idiosyncrasy to medicinal products or excipients. Positive HIV test. Positive hepatitis B or C test. Pregnant female (as confirmed by an Human chorionic gonadotropin (hCG) test performed less than 4 weeks before day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal (...) . They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the study. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen (max 2 gram/day). Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disorders, renal and hepatic disorders (increased alanine aminotransferase (ALAT)/ASAT), hormonal

2015 Clinical Trials

16. TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine

Phase of the Migraine (Studies 1 and 2 of 2) Condition or disease Intervention/treatment Phase Migraine Disorders Migraine, Acute Drug: TREXIMET® Drug: Butalbital-containing Combination Medications (BCM) Drug: placebo Phase 3 Detailed Description: This study is a multicenter, randomized, double-blind, double-dummy, placebo-controlled, crossover, three-attack, outpatient study in which TREXIMET® will be compared to a butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine (...) 40mg, and butalbital 50mg [Fioricet]) for the acute treatment of migraine headaches. Subjects will be randomized to one of 6 possible treatment sequences (TPB, TBP, BTP, BPT, PTB, PBT where T = TREXIMET®; P = Placebo; B = Butalbital-containing Combination Medication) . Subjects will treat each of the 3 migraine attacks when pain is moderate to severe. The study will include 4 visits: (1) a Screening visit at study entry, (2) a Drug Screen visit, (3) a Randomization visit, and (4) a Final visit

2013 Clinical Trials

17. Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

prior to screening. Experiences 4-14 migraine headache days per month during the baseline period. Ability and willingness to abstain from taking medications not allowed by the protocol or administering any foreign substance intranasally. Ability and willingness to complete a migraine-history diary from screening to treatment with study drug and a migraine-treatment diary from prevention treatment through the remainder of the follow-up period. Exclusion Criteria: Headache on greater than 14 days (...) of the study. Use of analgesics (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], acetylsalicylic acid, or combination analgesics) for migraine and non-migraine headaches on more than 14 days per month in the - Use of migraine prevention medication within two months prior to study and throughout the duration of the study. Botulinum toxin injection within 3 months prior to screening or during study. Anti-CGRP monoclonal antibody (e.g., erenumab, fremanezumab, galcanezumab

2018 Clinical Trials

18. A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

medication to reduce the frequency of migraine episodes within 3 months prior to screening Pregnant or breast-feeding women History of drug or alcohol abuse/dependence within 1 year prior to screening Any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study Currently enrolled in any other clinical study involving an investigational product Relatives of, or staff directly reporting to, the Investigator Participants who (...) months MIDAS score ≥11 Able and willing to complete an eDiary to record the details of each migraine attack treated with study drug Women of child-bearing potential must be using or willing to use a highly effective form of contraception Agree not to post any personal medical data or information related to the study on any website or social media site until the entire trial has completed Exclusion Criteria: Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets History

2018 Clinical Trials

19. CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment

for migraine Women of childbearing potential are on safe contraception Exclusion Criteria: Women of childbearing potential who do not use contraception. Includes non-hysterectomized women who have not been menopausal for at least two years. Safe contraception includes condoms, intrauterine devices, p-pills, surgical sterilization or gestagen injections. Daily drug intake apart from contraceptives and preventive medication for migraine. Ingestion of any drug 4 half-lifes before study start apart from (...) contraceptives. Pregnant or breast-feeding women Migraine on the study day or less than 48 hours before CGRP infusion. A history of cardiovascular and/or cerebrovascular disease Systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg on study day. Systolic blood pressure <90 mmHg and/or diastolic blood pressure < 50 mmHg on study day. A history of mental illness A history of any illness or condition that is deemed relevant for participation by the investigator. Contacts and Locations Go

2018 Clinical Trials

20. 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

requiring medication Medical illness including cancer, coronary artery or cerebrovascular disease Known allergy to one of the test medications Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures Taking migraine prophylactic medication or vestibular suppressants. Pregnant or breast feeding women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study (...) in the Treatment of Patients With Vestibular Migraine Estimated Study Start Date : January 2019 Estimated Primary Completion Date : January 2023 Estimated Study Completion Date : January 2024 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 4-AP 15 mg 4-aminopyridine twice daily Drug: 4-aminopyridine an oral drug to be swallowed Experimental: Atenolol 25 mg atenolol twice daily Drug

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>